Supplements
vitamin C treats sepsis
In plain terms: Does intravenous vitamin C help treat sepsis?
Leans against Supplements 💰 Industry COI noted🔬 Includes disconfirming
Part of: 🧪 vitamin C
RefutedContestedStrong support
consensus score -0.25
No—early hopeful trials were overturned; the landmark LOVIT trial and the largest analyses show no benefit and a possible harm signal.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
3 support 5 contradict 0 tested null 3 mixed · 11 sources, 8 independent groups
What the evidence shows
High-dose intravenous vitamin C is not an established sepsis treatment and may be harmful. The evidence is genuinely mixed but nets negative: several pre-LOVIT meta-analyses of small trials reported a mortality benefit (e.g. OR 0.
The evidence (14)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Chang P, Liao Y, Guan J, Guo Y, Zhao M, Hu J, Zhou J, Wang H, Cen Z, Tang Y, Liu Z 2020 · Chest | RCT | mixed | moderate | RCT of HAT (hydrocortisone+vit C+thiamine): no clear mortality reduction (combination therapy — cannot isolate vitamin C). |
| Xing X, Xu M, Yang L, Zhang W, Niu X, Gao D 2021 · Clin Nutr | meta-analysis | supports | moderate | Pre-LOVIT MA: IV vit C reported beneficial for some critically-ill outcomes (later contradicted by larger trials). |
| Kanji S, Hernández-Mitre MP, Blain H, Adhikari NKJ, Lamontagne F, Battista MC, Ménard J, Sprague S, Masse MH, Roberts JA, LOVIT Investigators 2026 · Clinical pharmacokinetics | RCT | contradicts | high | LOVIT trial PK sub-study (n=161 vitC arm). Non-survivors had higher vitC exposure than survivors (p<0.001) but on multivariable analysis exposure was NOT independently associated with 28-day mortality; only age and APACHE II were. |
| Chen Y, Lu M, Shi X, Feng F, Zhou J 2026 · International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition | RCT | contradicts | moderate | Pilot RCT, n=40 sepsis patients. VitC reduced septic AKI incidence (25% vs 70%, p=0.004) and RRT need, but ICU mortality NOT significantly different (10% vs 15%, p=0.633). |
| Plummer MP, Bellomo R 2022 · Nat Rev Nephrol | observational | contradicts | low | Analysis of LOVIT + CLASSIC trials: high-dose IV vitamin C might be HARMFUL in severe sepsis (higher risk of death/persistent organ dysfunction). |
| Ahmed R, Shetty S, Aziz Khan MQ, Kalsoom I, Qasim S, Khan SB, Abdullah S 2026 · Cureus | meta-analysis | mixed | moderate | Systematic review 2020-2025, 5 studies (RCTs, cohorts, meta-analyses). Modest physiologic benefits (SOFA, vasopressor duration) but 'consistent improvement in mortality...remains unproven.' |
| Brown J, Robertson C, Sevilla L, Garza J, Rashid H, Benitez AC, Shipotko M, Ali Z 2022 · Cureus | meta-analysis | contradicts | moderate | SRMA (18 studies, 4078 pts): no mortality reduction and no effect on SOFA, ICU stay, vasopressor or ventilation duration. |
| Vera-Ponce VJ, Ballena-Caicedo J, Valladolid-Sandoval LAM, Zuzunaga-Montoya FE, Acosta-Porzoliz R, Rivera-Lozada O, Valladares-Garrido MJ 2026 · PLoS One | meta-analysis | mixed | high | Umbrella review of 31 systematic reviews; 'No new meta-analyses or meta-regressions were performed.' Reports combinations 'did not reduce mortality' and monotherapy 'a possible mortality benefit signal under specific conditions ... with low-to-moderate certainty'. Units are syntheses — review, zero weight. |
| Feng F, Yang H, Yang W, Li M, Chang X, Chen Y 2021 · Sci Prog | meta-analysis | supports | low | Pre-LOVIT MA (9 RCTs, 584 pts): vit C reduced 28-day mortality (OR 0.60) — the earlier optimistic signal, since overturned. |
| Lee ZY, Ortiz-Reyes L, Lew CCH, Hasan MS, Ke L, Patel JJ, Stoppe C, Heyland DK 2023 · Ann Intensive Care | meta-analysis | supports | low | Updated SRMA + trial-sequential analysis of IV vitamin C MONOTHERAPY in critically ill adults, 16 RCTs (n=2130) — a critically-ill pool, not a sepsis-only one: 'Ten (62.5%) studies enrolled patients with sepsis', and the a priori sepsis vs non-sepsis subgroup showed no difference. With LOVIT INCLUDED, the pooled estimate still favours vitamin C: overall mortality RR 0.73 (95% CI 0.60–0.89; p=0.002; I2=42%; 16 studies) and 28-day mortality RR 0.71 (95% CI 0.53–0.95; 9 studies); TSA supported this at RRR 30% and 25%, the fixed-effect sensitivity analysis held (RR 0.83), and no funnel-plot asymmetry was detected (p=0.54). The authors state: 'when we examined the whole corpus of evidence including the LOVIT trial results, we found mortality benefits of IVVC monotherapy, albeit with low certainty'. Counterweights inside the same paper: longer-term (>=60-day) mortality NULL (RR 0.98, 95% CI 0.82–1.19; 4 studies), and no effect on ventilation duration, ICU/hospital stay, SOFA at 96 h, vasopressor dose, AKI or RRT; subgroup/TSA analyses were largely post-hoc and unadjusted for multiplicity, which the authors call 'hypothesis-generating'. Certainty of the primary finding rated LOW by the authors' own GRADE assessment (only 3/16 trials at low risk of bias; I2=42%). COI: senior authors DKH and CS are investigators on VICToRY (NCT04138394), a vitamin C trial with product support from vitamin C manufacturers. |
| Radke DI, Homayr AL, Stoppe C, Elke G 2023 · Curr Opin Crit Care | observational | contradicts | low | Review of high-dose vitamin C monotherapy in critical illness: recent RCT evidence negative — 'end of the story' for routine use. |
| Alangari A, Arif J, Al Qureshah F, Alkhodairy F 2026 · Journal of medicine and life | observational | contradicts | moderate | PRISMA-informed review of high-dose IV vitC (2010-2025), prioritizing RCTs/SRs. Conclusion: 'evidence does not support routine use of high-dose IVC in sepsis'; risks include oxalate nephropathy, hemolysis in G6PD deficiency. |
| Fujii T, Salanti G, Belletti A, Bellomo R, Carr A, Furukawa TA, Luethi N, Luo Y, Putzu A, Sartini C, Tsujimoto Y, Udy AA, Yanase F, Young PJ 2022 · Intensive Care Med | meta-analysis | contradicts | high | Component NMA (43 RCTs, 10,257 pts, CINeMA): vitamin C alone or in metabolic-resuscitation combos NOT associated with lower longer-term mortality; no effect on organ dysfunction or ICU stay. |
| Hung KC, Chuang MH, Chen JY, Hsu CW, Chiu CC, Chang YJ, Lee CW, Chen IW, Sun CK 2023 · Front Nutr | meta-analysis | mixed | moderate | MA + TSA of IV vit C monotherapy on mortality: information size insufficient — no firm mortality benefit established. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.